GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Chordate Medical Holding AB (OSTO:CMH) » Definitions » Price-to-Owner-Earnings

Chordate Medical Holding AB (OSTO:CMH) Price-to-Owner-Earnings : (As of May. 24, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Chordate Medical Holding AB Price-to-Owner-Earnings?

As of today (2024-05-24), Chordate Medical Holding AB's share price is kr0.05. Chordate Medical Holding AB does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Chordate Medical Holding AB's Price-to-Owner-Earnings or its related term are showing as below:


OSTO:CMH's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 34.285
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-24), Chordate Medical Holding AB's share price is kr0.05. Chordate Medical Holding AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was kr-0.10. Therefore, Chordate Medical Holding AB's PE Ratio for today is At Loss.

As of today (2024-05-24), Chordate Medical Holding AB's share price is kr0.05. Chordate Medical Holding AB's EPS without NRI for the trailing twelve months (TTM) ended in was kr-0.10. Therefore, Chordate Medical Holding AB's PE Ratio without NRI for today is At Loss.


Chordate Medical Holding AB Price-to-Owner-Earnings Historical Data

The historical data trend for Chordate Medical Holding AB's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chordate Medical Holding AB Price-to-Owner-Earnings Chart

Chordate Medical Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only - - - - -

Chordate Medical Holding AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Chordate Medical Holding AB's Price-to-Owner-Earnings

For the Medical Devices subindustry, Chordate Medical Holding AB's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chordate Medical Holding AB's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Chordate Medical Holding AB's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Chordate Medical Holding AB's Price-to-Owner-Earnings falls into.



Chordate Medical Holding AB Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Chordate Medical Holding AB's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.05/-0.09
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chordate Medical Holding AB  (OSTO:CMH) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Chordate Medical Holding AB Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Chordate Medical Holding AB's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Chordate Medical Holding AB (OSTO:CMH) Business Description

Traded in Other Exchanges
Address
c/o Regus, Kistagangen 20B, Kista, SWE, 164 40
Chordate Medical Holding AB is a medical technology company that has developed and patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients who are 18 years old or older. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.

Chordate Medical Holding AB (OSTO:CMH) Headlines

No Headlines